<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2250">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575038</url>
  </required_header>
  <id_info>
    <org_study_id>CCB-CRISIS-02</org_study_id>
    <nct_id>NCT04575038</nct_id>
  </id_info>
  <brief_title>CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19</brief_title>
  <acronym>CRISIS2</acronym>
  <official_title>The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clear Creek Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clear Creek Bio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5&#xD;
      days of treatment of participants with positive COVID-19 and at least one symptom of COVI019&#xD;
      in an out-patient setting. The study is multi-center, randomized, and placebo-controlled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brequinar is a potent DHODH inhibitor that has been previously studied in more than 1,000&#xD;
      cancer, psoriasis, and organ transplant patients. Brequinar has been found to have potent in&#xD;
      vitro antiviral activity against many RNA viruses including SARS-CoV-2. The antiviral&#xD;
      activity of brequinar against SARS-CoV-2 is likely due to DHODH inhibition and shows&#xD;
      nanomolar potency and a high selectivity index in inhibiting viral replication in in vitro&#xD;
      studies.&#xD;
&#xD;
      The CRISIS2 trial will study out-patients (non-hospitalized patients) who have a positive&#xD;
      SARS-CoV-2 test and are symptomatic. Subjects will be randomized to receive standard of care&#xD;
      (SOC) + 5 days of brequinar or SOC + 5 days of placebo. The purpose of this study is to&#xD;
      determine if the in vitro antiviral activity of brequinar can be duplicated in patients&#xD;
      infected with SARS-CoV-2 by measuring the effect of brequinar on viral shedding. Importantly,&#xD;
      the safety and tolerability of brequinar will also be determined in these patients. The&#xD;
      results of this proof-of-concept study will inform future studies that will help determine if&#xD;
      brequinar is a safe and effective drug for the treatment of SARS-CoV-2 infection.&#xD;
&#xD;
      This will be a phase II randomized, placebo-controlled, double blind, multi-center study with&#xD;
      approximately 100 subjects. All subjects will receive standard of care (SOC) per&#xD;
      institutional guidelines for treatment of patients with COVID-19 infection. In addition to&#xD;
      SOC, the subjects will self-administer one capsule once daily for 5 days.&#xD;
&#xD;
      Subjects will have a Screening Visit followed as soon as possible with Study Day 1. Study&#xD;
      visits (virtual or in person) will take place at Screening and on specified days. The visits&#xD;
      that include bloodwork must be conducted at the study site or arrangements made for sample&#xD;
      collection at the subject's home or other appropriate location. Other visits/visit activities&#xD;
      for that visit may be conducted remotely using telemedicine or other remote technique.&#xD;
      Subjects are to self-collect a viral load sample, obtain their respiratory rate, heart rate,&#xD;
      body temperature and SpO2, and complete a symptom assessment checklist on specified days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 1:1 brequinar 100 mg or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 viral load</measure>
    <time_frame>Day 29</time_frame>
    <description>Quantitative SARS-CoV-2 viral load</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of AEs and SAEs including laboratory assessments</measure>
    <time_frame>Day 29</time_frame>
    <description>Safety measured by rates of AEs and SAEs including laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral shedding duration</measure>
    <time_frame>Day 29</time_frame>
    <description>Duration of viral shedding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Admission</measure>
    <time_frame>Day 29</time_frame>
    <description>Percentage of subjects requiring admission as an inpatient for &gt;24 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19 Infection</condition>
  <arm_group>
    <arm_group_label>Brequinar 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brequinar oral capsules 100 mg x 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for Brequinar capsules x 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brequinar</intervention_name>
    <description>Dihydroorotate dehydrogenase inhibitor (DHODHi)</description>
    <arm_group_label>Brequinar 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide informed consent for the trial, written, electronic,&#xD;
             verbal or other method deemed acceptable by the institution and IRB.&#xD;
&#xD;
          2. 18 years of age or older.&#xD;
&#xD;
          3. Laboratory-confirmed SARS-CoV-2 infection as determined by real time polymerase chain&#xD;
             reaction (RT-PCR) or other FDA-approved commercial or public health assay.&#xD;
&#xD;
          4. Out-patient (never hospitalized as an in-patient for COVID-19 or was evaluated/treated&#xD;
             for COVID-19 only in the Emergency Room with a stay of &lt; 24 hours)&#xD;
&#xD;
          5. The effects of brequinar on the developing human fetus are unknown. For this reason,&#xD;
             women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation. Should a woman become pregnant or suspect she is&#xD;
             pregnant while she or her partner is participating in this study, she should inform&#xD;
             her treating physician immediately. Men and women treated or enrolled on this protocol&#xD;
             must also agree to use adequate contraception for the duration of study participation,&#xD;
             and for 90 days after completion of brequinar administration.&#xD;
&#xD;
          6. Male subjects must agree to refrain from sperm donation and female subjects must agree&#xD;
             to refrain from ovum donation from initial study drug administration until 90 days&#xD;
             after the last dose of brequinar.&#xD;
&#xD;
          7. Must have at least one COVID-19 symptom including but not limited to fever, cough,&#xD;
             sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of&#xD;
             breath, dyspnea, anosmia, dysgeusia, or other symptom commonly associated with&#xD;
             COVID-19 in the opinion of the investigator. Symptom onset must be ≤7 days prior to&#xD;
             first dose. Subject must have one or more symptoms at first dose.&#xD;
&#xD;
          8. Able to swallow capsules.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any physical examination findings and/or history of any illness that, in the opinion&#xD;
             of the study investigator, might confound the results of the study or pose an&#xD;
             additional risk to the patient&#xD;
&#xD;
          2. Nursing women or women of childbearing potential (WOCBP) with a positive pregnancy&#xD;
             test&#xD;
&#xD;
          3. Treatment with another DHODH inhibitor (e.g., leflunomide, teriflunomide) or other&#xD;
             agents known to cause bone marrow suppression leading to thrombocytopenia&#xD;
&#xD;
          4. Platelets ≤150,000 cell/mm3&#xD;
&#xD;
          5. Hemoglobin &lt; 10 gm/dL&#xD;
&#xD;
          6. Absolute neutrophil count &lt; 1500 cells/mm3&#xD;
&#xD;
          7. Renal dysfunction, i.e., creatinine clearance &lt; 30 mL/min&#xD;
&#xD;
          8. AST or ALT &gt; 2 x ULN, or total bilirubin &gt; ULN. Gilbert's Syndrome is allowed.&#xD;
&#xD;
          9. Bleeding disorders or blood loss requiring transfusion in the six weeks preceding&#xD;
             enrollment&#xD;
&#xD;
         10. Ongoing gastrointestinal ulcer, or gastrointestinal bleeding within 6 weeks of&#xD;
             randomization.&#xD;
&#xD;
         11. Chronic hepatitis B infection, active hepatitis C infection, active liver disease&#xD;
             and/or cirrhosis per subject report.&#xD;
&#xD;
         12. Heart failure, current uncontrolled cardiovascular disease, including unstable angina,&#xD;
             uncontrolled arrhythmias, major adverse cardiac event within 6 months (e.g. stroke,&#xD;
             myocardial infarction, hospitalization due to heart failure, or revascularization&#xD;
             procedure).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barbara L Powers, PhD</last_name>
    <phone>(617) 765-2252</phone>
    <email>clinical@clearcreekbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Alabama Research</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barry McLean, PD, Ph.D.</last_name>
      <phone>205-949-1906</phone>
      <email>bmclean@centralalabamaresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ark Clinical Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akanksha Nanda, MD</last_name>
      <phone>562-997-1000</phone>
      <email>info@arkclinicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doral Medical Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Nava</last_name>
      <phone>305-821-6112</phone>
      <email>andoralmedresearch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Jersey Infectious Disease</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Lucasti, DO, FACOI</last_name>
      <phone>609-927-6662</phone>
      <email>infect123@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monroe Biomedical Research</name>
      <address>
        <city>Monroe</city>
        <state>North Carolina</state>
        <zip>28112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suvi Gross</last_name>
      <phone>704-283-7359</phone>
      <email>suvi.gross@monroeresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilmington Health</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Clancey, MS</last_name>
      <phone>910-341-1321</phone>
      <email>jclancey@wilmingtonhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Remington-Davis, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Team</last_name>
      <phone>614-487-2560</phone>
      <email>info@remdavis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo Institute of Clinical Research</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabia Gilani, PhD</last_name>
      <phone>419-843-8815</phone>
      <email>rabia.gilani@ohmiallergy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VitaLink - Gaffney</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David R Erb, MD, FCCP</last_name>
      <phone>864-488-1283</phone>
      <email>derb.md@vitalinkresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Self Regional Healthcare Research Center - Self Medical Group</name>
      <address>
        <city>Greenwood</city>
        <state>South Carolina</state>
        <zip>29646</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Rich</last_name>
      <phone>864-943-2416</phone>
      <email>Heather.Rich@selfregional.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VitaLink Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Feldman, MD</last_name>
      <phone>864-515-0092</phone>
      <email>gfeldman.md@vitalinkresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Center of Middle Tennessee</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex J Slandzicki, MD</last_name>
      <phone>615-205-8350</phone>
      <email>jslandzicki@ctcmidtn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc. - McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Solis, MD</last_name>
      <phone>956-540-7170</phone>
      <email>jsolis@centexstudies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc. - Olympus Family Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Garcia</last_name>
      <phone>385-367-6166</phone>
      <email>davidgarcia@cctresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brequinar</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

